Revised forecast
the fiscal year ending March 2027 · Interim consolidated accounting period and full fiscal yearPrevious forecast published 12 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue exceeded the forecast due to a recovery in orders for the company's core overseas products, including circuits for apheresis blood collection and blood bags, and increased sales of priority products in Japan, including closed systems for drug preparation and administration. However, profit is expected to fall below the forecast due to the impact of low utilization at overseas production sites in the first quarter and through the first half, persistently high raw material costs and prices, heightened tensions in the Middle East, and the recording of foreign exchange losses.
| Item | Details |
|---|---|
| Net Sales | Interim period 31,600 / Full year 66,000 → Interim period 32,391 / Full year 68,000（Interim period 2.5% / Full year 3.0%） |
| Operating profit | Interim period 350 / Full year 1,000 → Interim period 9 / Full year 700（Interim period △97.3% / Full year △30.0%） |
| Ordinary income | Interim period 300 / Full year 900 → Interim period -145 / Full year 400（Interim period Not disclosed / Full year △55.6%） |
| Profit attributable to owners of the parent | Interim period 200 / Full year 600 → Interim period -262 / Full year 100（Interim period Not disclosed / Full year △83.3%） |
| Net income per share | Interim period ¥8.16 / Full year ¥24.47 → Interim period -¥10.69 / Full year ¥4.07 |
| Fiscal Period Covered | the fiscal year ending March 2027 |
| Period Covered | Interim consolidated accounting period and full fiscal year |
| Publication date of previous forecast | 12 May 2026 |
| Previous-period results | Interim period Revenue ¥32,216 million, operating loss ¥19 million, ordinary loss ¥46 million, interim net loss attributable to owners of the parent ¥190 million, interim net loss per share ¥7.78 (interim period of the fiscal year ended March 2026) / Full year Revenue ¥65,845 million, operating profit ¥381 million, ordinary profit ¥356 million, net loss attributable to owners of the parent ¥783 million, net loss per share ¥31.97 (fiscal year ended March 2026) |
| Reason for the revision | Revenue exceeded the forecast due to a recovery in orders for the company's core overseas products, including circuits for apheresis blood collection and blood bags, and increased sales of priority products in Japan, including closed systems for drug preparation and administration. However, profit is expected to fall below the forecast due to the impact of low utilization at overseas production sites in the first quarter and through the first half, persistently high raw material costs and prices, heightened tensions in the Middle East, and the recording of foreign exchange losses. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue exceeded the forecast due to a recovery in orders for the company's core overseas products and expanded sales of priority products in Japan. However, the impact of low utilization at overseas production sites persisted, while rising raw material and other costs associated with heightened tensions in the Middle East, the cost burden from persistently high raw material and other prices, and the recording of foreign exchange losses weighed on profit.